Bioage Labs, INC Form 4 insider transactions

Shane Barton, Principal Accounting Officer of BioAge Labs, purchased 2,632 shares of common stock at $18 per share through a directed share program related to the company's IPO.

Eric Morgen's spouse receives a stock option award from BioAge Labs, prompting an amendment to a previous SEC Form 4 filing.

Paul D. Rubin, Chief Medical Officer of BioAge Labs, reports the acquisition of stock options in the company.

Eric Morgen, Chief Operating Officer of BioAge Labs, acquired 200,000 stock options on February 18, 2025, according to a Form 4 filing with the SEC.

BioAge Labs' Chief Financial Officer, Dov Goldstein, reports the acquisition of 170,000 stock options in the company.

BioAge Labs CEO Kristen Fortney reports the acquisition of 530,000 stock options with an exercise price of $4.38, vesting monthly from February 1, 2025.

Shane Barton, Principal Accounting Officer of BioAge Labs, acquired 90,000 stock options on February 18, 2025, according to a Form 4 filing with the SEC.

BioAge Labs' Principal Accounting Officer, Shane Barton, was granted 40,000 stock options on December 18, 2024, according to a recent SEC filing.

Director Vijay Satyanand Pande reported the acquisition of BioAge Labs shares through indirect holdings across multiple funds.

Cormorant Asset Management and related entities report conversion of preferred stock and purchase of common stock in BioAge Labs following its initial public offering.

Director Vijay Satyanand Pande reports the conversion of preferred stock to common stock and acquisition of common stock through various entities following BioAge Labs' initial public offering.

Director Patrick Enright reports acquisition and conversion of BioAge Labs stock, including shares from Longitude Venture Partners IV, L.P., and a new stock option grant.

BioAge Labs CEO Kristen Fortney reports the acquisition of stock options, including those acquired through an exempt transaction.

Director James Healy reports acquisition of BioAge Labs common stock through private placement and conversion of preferred stock, along with stock options.

Director Rekha Hemrajani reports acquisition of stock options in BioAge Labs, Inc.

Michael H. Davidson, a director at BioAge Labs, acquired stock options, as reported in a recent SEC filing.

Jean Pierre Garnier, a director at BioAge Labs, acquired options to purchase company stock, as reported in a recent SEC filing.

Eric Morgen, Chief Operating Officer of BioAge Labs, reports the acquisition of stock options.